<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02366312</url>
  </required_header>
  <id_info>
    <org_study_id>15-00254</org_study_id>
    <secondary_id>ML28859</secondary_id>
    <nct_id>NCT02366312</nct_id>
  </id_info>
  <brief_title>A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors</brief_title>
  <acronym>KCOT</acronym>
  <official_title>A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU College of Dentistry</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU College of Dentistry</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how well a daily dose of 150 mg of Erivedge&#xD;
      (vismodegib) reduces Keratocystic odontogenic tumor (KCOT) size, and to evaluate the safety&#xD;
      of this dose. Erivedge is FDA-approved for use in adults with a specific type of skin cancer.&#xD;
      However, the drug is experimental for patients with KCOT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, interventional, single-arm, open-label, two-cohort clinical trial. A&#xD;
      total of 20 patients will be enrolled (10 with NBCCS-associated KCOT and 10 with sporadic&#xD;
      KCOT) over a period of 2 years. This is a 3 year study where each patient will undergo up to&#xD;
      1 year of treatment and up to 2 years of post-treatment follow-up.&#xD;
&#xD;
      All patients will be assessed for safety and efficacy of the study drug GDC-0449&#xD;
      (Vismodegib).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 27, 2015</start_date>
  <completion_date type="Actual">August 2019</completion_date>
  <primary_completion_date type="Actual">August 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>KCOT Volume (Greatest Dimension)</measure>
    <time_frame>Baseline, 6 month (in treatment), 1 year (in treatment), 2 Year (post-treatment), 3 Year (post-treatment)</time_frame>
    <description>To evaluate the efficacy of GDC-0449 in reducing KCOT size (shrinkage) in NBCCS-associated KCOT and sporadic KCOT patients following 6 to 12 months of ingestion of 150 mg/day, up to 1 year of treatment and up to 2 years of post- treatment follow-up.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Keratocystic Odontogenic Tumor</condition>
  <arm_group>
    <arm_group_label>vismodegib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The 150-mg vismodegib drug product is a hard gelatin capsule formulation for oral administration. This study involves one year of treatment with Erivedge (150 mg/day) plus two years of follow-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vismodegib</intervention_name>
    <description>vismodegib is a synthetic, small molecule inhibitor of the sonic Hh pathway, which is involved in tumorigenesis, thus providing a strong rationale for its use in the treatment of a variety of cancers.</description>
    <arm_group_label>vismodegib</arm_group_label>
    <other_name>ERIVEDGEÂ®, GDC-0449</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females, 18 years of age and above at the time the informed consent form is&#xD;
             signed;&#xD;
&#xD;
          -  Able to understand and sign the Informed Consent Form and other necessary paperwork&#xD;
             prior to initiation of study procedures;&#xD;
&#xD;
          -  Able to communicate with the investigator/study site personnel, understand and comply&#xD;
             with the study requirements, and willing to return for specified visits at the&#xD;
             appointed time;&#xD;
&#xD;
          -  Patients who have received prior treatment for their KCOT and with a diagnosis of&#xD;
             recurrent (maxillary or mandibular) sporadic KCOT or NBCCS-associated KCOT (single or&#xD;
             multiple);&#xD;
&#xD;
          -  Diagnosis of KCOT will be done by past pathology report or by biopsy at the study&#xD;
             site, if applicable;&#xD;
&#xD;
          -  Willingness to consent to biopsy of the lesion, if needed;&#xD;
&#xD;
          -  Willingness to delay excision of the target tumor site, unless evidence of disease&#xD;
             progression or lack of drug tolerability;&#xD;
&#xD;
          -  Willingness to donate blood for genetic testing;&#xD;
&#xD;
          -  For female patients of childbearing potential, agreement to use two acceptable methods&#xD;
             of birth control, including one barrier method during the study and 7 months after&#xD;
             discontinuation of study drug;&#xD;
&#xD;
          -  For males with female partners of childbearing potential, agreement to use a male&#xD;
             condom (with spermicide) and to advise their female partners to use an acceptable&#xD;
             method of birth control during the study and for 2 months after the discontinuation of&#xD;
             the study drug;&#xD;
&#xD;
          -  Agreement not to donate blood/blood products during the study and for 7 months after&#xD;
             the discontinuation of the study drug;&#xD;
&#xD;
          -  For males not to donate sperm products or semen during treatment and for 2 months&#xD;
             after the discontinuation of the study drug;&#xD;
&#xD;
          -  Able and willing to swallow pill;&#xD;
&#xD;
          -  No malabsorption syndrome or other condition that would interfere with enteral&#xD;
             absorption;&#xD;
&#xD;
          -  At least 4 weeks since last chemotherapy, investigational therapy, radiotherapy or&#xD;
             major surgical procedure and recovered from the first study drug administration;&#xD;
&#xD;
          -  KCOT measures at least 1 cm in one dimension on pretreatment volumetric CT scan;&#xD;
&#xD;
          -  No clinically significant abnormalities with clinical laboratory assessments;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent anti-tumor therapy;&#xD;
&#xD;
          -  Completion of the most recent anti-tumor therapy (including Vismodegib) less than 4&#xD;
             weeks prior to the initiation of treatment (first study drug administration);&#xD;
&#xD;
          -  Uncontrolled medical illness;&#xD;
&#xD;
          -  Pregnancy or lactation; female patients who are planning to become pregnant for the&#xD;
             duration of the study and 7 months post-treatment;&#xD;
&#xD;
          -  Inability or unwillingness to swallow capsules;&#xD;
&#xD;
          -  Any medical or psychological illness or condition preventing adequate consent;&#xD;
&#xD;
          -  History of significant atherosclerotic disease, including the following:&#xD;
&#xD;
               -  Coronary artery disease (i.e., myocardial infarction within the past year or&#xD;
                  unstable angina);&#xD;
&#xD;
               -  Documented carotid atheroma;&#xD;
&#xD;
          -  Known HIV infection;&#xD;
&#xD;
          -  Current alcohol abuse;&#xD;
&#xD;
          -  History of resistance to vismodegib (patients who previous received vismodegib for BCC&#xD;
             and had no clinical response will be excluded).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian L Schmidt, DDS, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU College of Dentistry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Bluestone Center For Cllinical Research</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 5, 2015</study_first_submitted>
  <study_first_submitted_qc>February 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <results_first_submitted>December 21, 2020</results_first_submitted>
  <results_first_submitted_qc>February 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 18, 2021</results_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NYU College of Dentistry</investigator_affiliation>
    <investigator_full_name>Brian L. Schmidt</investigator_full_name>
    <investigator_title>Director, Bluestone Center for Clinical Research</investigator_title>
  </responsible_party>
  <keyword>Keratocystic odontogenic tumor</keyword>
  <keyword>KCOT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Odontogenic Tumors</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 14, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT02366312/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 20, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT02366312/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited at the NYU Oral cancer center between mmyy and mmyy. The first participant was enrolled in mmyy and the last subject was enrolled in mmyy.</recruitment_details>
      <pre_assignment_details>Of 3 enrolled subjects, 2 met inclusion criteria and received treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>NBCCS-associated KCOT</title>
          <description>Nevoid Basal Cell Carcinoma Syndrome (NBCCS)-associated Keratocystic Odontogenic Tumor (KCOT) Group</description>
        </group>
        <group group_id="P2">
          <title>Sporadic KCOT</title>
          <description>Sporadic Keratocystic Odontogenic Tumor (KCOT) Group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0">The subject did not attend the 2-year post-treatment visit (last visit).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NBCCS-associated KCOT</title>
          <description>Nevoid Basal Cell Carcinoma Syndrome (NBCCS)-associated Keratocystic Odontogenic Tumor (KCOT) Group</description>
        </group>
        <group group_id="B2">
          <title>Sporadic KCOT</title>
          <description>Sporadic Keratocystic Odontogenic Tumor (KCOT) Group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White - Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary KCOT Tumor size at Baseline</title>
          <description>Volumetric CT Scan to capture primary KCOT lesion size (greatest dimension) at baseline</description>
          <units>centimeter</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3.8"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>KCOT Volume (Greatest Dimension)</title>
        <description>To evaluate the efficacy of GDC-0449 in reducing KCOT size (shrinkage) in NBCCS-associated KCOT and sporadic KCOT patients following 6 to 12 months of ingestion of 150 mg/day, up to 1 year of treatment and up to 2 years of post- treatment follow-up.</description>
        <time_frame>Baseline, 6 month (in treatment), 1 year (in treatment), 2 Year (post-treatment), 3 Year (post-treatment)</time_frame>
        <population>Subjects received ERIVEDGEÂ® (vismodegib) 150 mg capsule orally once daily for 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>NBCCS-associated KCOT</title>
            <description>Nevoid Basal Cell Carcinoma Syndrome (NBCCS)-associated Keratocystic Odontogenic Tumor (KCOT) Group</description>
          </group>
          <group group_id="O2">
            <title>Sporadic KCOT</title>
            <description>Sporadic Keratocystic Odontogenic Tumor (KCOT) Group</description>
          </group>
        </group_list>
        <measure>
          <title>KCOT Volume (Greatest Dimension)</title>
          <description>To evaluate the efficacy of GDC-0449 in reducing KCOT size (shrinkage) in NBCCS-associated KCOT and sporadic KCOT patients following 6 to 12 months of ingestion of 150 mg/day, up to 1 year of treatment and up to 2 years of post- treatment follow-up.</description>
          <population>Subjects received ERIVEDGEÂ® (vismodegib) 150 mg capsule orally once daily for 12 months.</population>
          <units>centimeter</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 month (In treatment)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year (In treatment)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year (post-treatment)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Year (post-treatment)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to three years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>NBCCS-associated KCOT</title>
          <description>Nevoid Basal Cell Carcinoma Syndrome (NBCCS)-associated Keratocystic Odontogenic Tumor (KCOT) Group</description>
        </group>
        <group group_id="E2">
          <title>Sporadic KCOT</title>
          <description>Sporadic Keratocystic Odontogenic Tumor (KCOT) Group</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>High grade Newuorendocrine Carcinoma of head/neck</sub_title>
                <description>Serious but not related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Earache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Non-serious / unlikely related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>bilateral lower extremities swelling</sub_title>
                <description>non-serious , unlikely related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>epigastric pain / non-serious / unlikely related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>GI upset</sub_title>
                <description>Non serious / Not related / possibly related</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Loose stool</sub_title>
                <description>non-serious, possible related</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>Right jaw pain / non serious / possibly related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>non-serious / unlikely related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <description>right face / non-serious / not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Cold symptoms</sub_title>
                <description>non-serious / not related</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Loss of taste</sub_title>
                <description>non-serious, possibly related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyn lesion</sub_title>
                <description>non serious, possibly related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cramping</sub_title>
                <description>Right hand cramping / non-serious / possibly related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>spasm</sub_title>
                <description>Left Quadricep Spasm / non-serious / probably related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Spasm</sub_title>
                <description>Both legs / non-serious / probably related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>cramp</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>finger cramping / non-serious / probably related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Leg Cramp</sub_title>
                <description>worsening of leg cramps / non-serious / probably related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Toes cramping</sub_title>
                <description>non-serious, possible related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>lower extremity pain</sub_title>
                <description>both sides, non-serious, possibly related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Right facial pain</sub_title>
                <description>non serious, possibly related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Left sided muscle ache</sub_title>
                <description>non-serious, not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Sacral injury</sub_title>
                <description>non-serious , not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Facial numbness</sub_title>
                <description>Right side / non-serious / probably related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <description>non-serious / unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <description>non-serious / not related / possible related</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hair loss</sub_title>
                <description>non-serious / possibly related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Enrollment for the study closed early by the sponsor due to low enrollment number. Only two subjects were enrolled and received the study treatment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Brian Schmidt</name_or_title>
      <organization>NYU College of Dentistry</organization>
      <phone>212-998-8900</phone>
      <email>brianl.schmidt@nyu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

